Shoot­ing for $100M IPO, Schrödinger takes the wraps off its five in­ter­nal drugs and dis­clos­es deal de­tails

Just be­fore last year’s JP Mor­gan con­fab kicked off, Schrödinger un­veiled its first ven­ture round fea­tur­ing in­sti­tu­tion­al in­vestors be­fore lat­er clos­ing the Se­ries E at $110 mil­lion. This time around, the com­pu­ta­tion­al drug dis­cov­ery ex­perts are in­sert­ing them­selves in­to the queue at the Nas­daq, gun­ning for a $100 mil­lion IPO.

Hav­ing honed its soft­ware ex­per­tise and built out its client base over three decades, Schrödinger boasts of a rev­enue stream that to­taled $66.6 mil­lion in 2018. But as it de­votes more of its at­ten­tion to its in­ter­nal pipeline, the New York com­pa­ny said it want­ed to in­crease their cap­i­tal­iza­tion and fi­nan­cial flex­i­bil­i­ty by en­ter­ing the pub­lic mar­ket. There’s al­so a hint of M&A plans to come.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER